Eczema Trial, Recruiting NCT06259669 Sponsor: Incyte Corporation Condition: Eczema
Back to Eczema

Eczema Trial, Recruiting

NCT06259669
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women between the ages of 15 and 50 who have been diagnosed with mild to moderate atopic dermatitis (a type of eczema).
  • People who are able to understand the study and are willing to formally agree to take part; for those under the legal age of adulthood, a parent or legal guardian must give consent on their behalf.
  • Women who are currently pregnant and can be enrolled while the pregnancy is ongoing, or women whose pregnancy has already ended within the last 12 months.
  • Women whose pregnancy either involved the use of ruxolitinib cream (at least once during pregnancy) or did not involve any use of ruxolitinib cream — both groups are being studied.
  • People for whom contact details are available so that the trial team can follow up over time.
  • People who give permission for the trial team to contact their own doctor and their baby's doctor.

Who may not be able to join:

  • Women whose pregnancy has already ended more than 12 months before they would be enrolled in the registry.
  • People who are currently taking, or have taken within the last 30 days (or longer, depending on the medication), another experimental or investigational medication, or who are already enrolled in another investigational drug study.
  • Pregnancies where the woman was exposed to any other medication in the same drug class as ruxolitinib (called JAK inhibitors) during a specific window from the start of pregnancy through at least the end of the first trimester, or through the full pregnancy for certain outcomes (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1.833.917.8791

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Incyte Corporation
Registry
ClinicalTrials.gov
Start date
13 September 2023
Est. completion
1 August 2032

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of major congenital malformation (MCM)s

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov